Literature DB >> 11684808

Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome.

R L Siegler1, T J Pysher, R Lou, V L Tesh, F B Taylor.   

Abstract

Shiga toxin (Stx) and lipopolysaccharide (LPS) both participate in the pathogenesis of post-diarrheal hemolytic uremic syndrome (HUS), yet little is known about the factors that modulate the host response to these toxins. We have previously shown that the baboon develops HUS if 100 ng/kg of purified Stx-1 is administered rapidly as a single bolus, but not if it is given as four 25-ng/kg doses every 12 h. We therefore used this baboon model to study the response to small intravenous doses of Stx-1, with and without the co-administration of LPS. The co-administration of two 1-mg/kg doses of LPS (given at 0 and 24 h) and four 25-ng/kg doses of Stx-1 (given at 0, 12, 24, and 36 h) resulted in HUS, but the administration of either toxin separately did not. The development of HUS was associated with a rise in urinary, but not plasma concentrations of TNF, and a rise in both urinary and plasma concentrations of IL-6 and IL-8. We speculate that LPS is not required for disease expression in the human, but that it can augment the response to otherwise subtoxic amounts of Stx and this augmentation may be mediated by LPS-induced cytokine release. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684808     DOI: 10.1159/000046288

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  17 in total

1.  Shiga toxin 2 and flagellin from shiga-toxigenic Escherichia coli superinduce interleukin-8 through synergistic effects on host stress-activated protein kinase activation.

Authors:  Dakshina M Jandhyala; Trisha J Rogers; Anne Kane; Adrienne W Paton; James C Paton; Cheleste M Thorpe
Journal:  Infect Immun       Date:  2010-05-03       Impact factor: 3.441

Review 2.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

3.  Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers.

Authors:  Leticia H Nolasco; Nancy A Turner; Aubrey Bernardo; Zhenyin Tao; Thomas G Cleary; Jing-Fei Dong; Joel L Moake
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

Review 4.  Shiga toxins expressed by human pathogenic bacteria induce immune responses in host cells.

Authors:  Moo-Seung Lee; Myung Hee Kim; Vernon L Tesh
Journal:  J Microbiol       Date:  2013-12-19       Impact factor: 3.422

Review 5.  Role of Shiga/Vero toxins in pathogenesis.

Authors:  Fumiko Obata; Tom Obrig
Journal:  Microbiol Spectr       Date:  2014-06

Review 6.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.

Authors:  Richard L Siegler; Tom G Obrig; Theodore J Pysher; Vernon L Tesh; Nathaniel D Denkers; Fletcher B Taylor
Journal:  Pediatr Nephrol       Date:  2003-01-10       Impact factor: 3.714

8.  Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.

Authors:  Kristin A D Sauter; Angela R Melton-Celsa; Kay Larkin; Megan L Troxell; Alison D O'Brien; Bruce E Magun
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

Review 9.  Renal and neurological involvement in typical Shiga toxin-associated HUS.

Authors:  Howard Trachtman; Catherine Austin; Maria Lewinski; Rolf A K Stahl
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

Review 10.  All blood, no stool: enterohemorrhagic Escherichia coli O157:H7 infection.

Authors:  Jang W Yoon; Carolyn J Hovde
Journal:  J Vet Sci       Date:  2008-09       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.